TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04738526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lithium disilicate (IPS e-max) ceramic crown
Description: monolithic lithium disilicate ceramic crown

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New gradient technology zirconia (5Y-TZP\ 3Y-TZP) IPS e.max ZirCad Prime ceramic crown
Description: conjunction with the two zirconium oxide raw materials 3Y-TZP and 5Y-TZP is responsible for producing a continuous, seamless progression of the shade and translucency within the material

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: natural tooth
Description: natural tooth is composed of enamel. Enamel is on the surface of every tooth and it has a natural hue of white. However, the underlying dentin layer has a slightly yellowish color. This yellowish hue shows through the enamel in almost everyone
Study: NCT06378892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Platinum-pemetrexed based chemotherapy plus Lorlatinib will be administered for an induction phase of four cycles. The choice between Carboplatin or Cisplatin is entrusted to the clinician. Subsequently, patients with response or stability of disease at radiological assessment will start the maintenance phase with pemetrexed-Lorlatinib in 21-day cycles until progression, unacceptable toxicity, death, or withdrawal of consent.
Study: NCT05786716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: An initial loading dose of 8 mg/kg body weight administered intravenously every 21 days followed thereafter by a maintenance dose of 6 mg/kg body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: An initial loading dose of 14 mg/kg administered intravenously every 21 days followed thereafter by a maintenance dose of 7 mg/kg.
Study: NCT06130826

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Receive M5A-IL2 ICK SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT04861987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCS6422 and capecitabine
Description: PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer. Capecitabine is a commonly used oral fluoropyrimidine.
Study: NCT06325969

Intervention type: DIAGNOSTIC_TEST
Intervention: Detect the immune function of peripheral blood samples
Description: Flow cytometry was used to detect the immune function of peripheral blood samples of PCOS patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: Detect the immune function of peripheral blood samples
Description: Flow cytometry was used to detect the immune function of peripheral blood samples of PCOS patients.
Study: NCT05054608

Intervention type: OTHER
Intervention: No intervention
Description: Observational study. No intervention.

Intervention type: OTHER
Intervention: No intervention
Description: Observational study. No intervention.

Intervention type: OTHER
Intervention: No intervention
Description: Observational study. No intervention.
Study: NCT06463288

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jacobsons Breathing Technique
Description: Quality of life, cough and sputum analysis, spirometry, and shortness of breath were assessed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pranayama Technique
Description: Quality of life, cough and sputum analysis, spirometry, and shortness of breath were assessed.
Study: NCT05896904

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Echocardiography
Study: NCT04716179

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Sperm test
Description: The semen sample will be collected and analyzed within an hour after collection.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sperm test
Description: The semen sample will be collected and analyzed within an hour after collection.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: hormone levels (testosterone, FSH, LH, prolactin)
Description: Hormone levels (testosterone, FSH, LH, prolactin) will be assessed on 5-7 days after symptom onset until the end of hospital stay.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: hormone levels (testosterone, FSH, LH, prolactin)
Description: Hormone levels (testosterone, FSH, LH, prolactin) will be assessed on 5-7 days after symptom onset until the end of hospital stay.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SARS-CoV-2 Ig G levels
Description: SARS-CoV-2 Ig G levels will be assessed on 3 months after discharge

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Ig G levels
Description: SARS-CoV-2 Ig G levels will be assessed on 3 months after discharge

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Testis pathology samples
Description: Postmortem examination of the testes of patients deceased as a result of COVID-19 infection will be carried out using immunohistochemistry analysis.
Study: NCT06578988

Intervention type: PROCEDURE
Intervention: Mammography Images
Description: Ultrasound and / or mammography are typically performed and reported by the imaging team at the same visit, with biopsy performed when indicated. This service is an important part of cancer care provision, with approximately half of the breast cancers diagnosed presenting via the symptomatic service rather than identified at screening.
Study: NCT06338657

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEOX-based Polymer Encapsulated Paclitaxel FID-007
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Resection
Description: Undergo surgical resection
Study: NCT05140161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: collagen
Description: use of hemostatic device in order to reduce bleeding in nail surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: collagen
Description: use of hemostatic device in order to reduce bleeding in nail surgery
Study: NCT05224921

Intervention type: OTHER
Intervention: Not applicable (cohort study)
Description: This is a prospective observational study and does not include interventions. The exposure is peripheral perfusion index and the outcome is the incidence of late onset sepsis. From the day when the very low birth weight infant is admitted into hospital, PPI monitoring should be recorded once a day, and continuous monitoring would be recorded until 1 month after birth. Before collection, the infant will be confirmed to be in supine position with neutral temperature, and at the same time, the infant will be in a quiet state, without the contact and operation of medical personnel.
Study: NCT04790305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier Granule
Description: The subjects in the experimental group will be treated with Huaier Granule continuously for 2 years or until the disease progressed, intolerable toxicity, withdrawal of informed consent form or died for any reason.
Study: NCT04779619

Intervention type: OTHER
Intervention: Online self-report questionnaire completion
Description: After reading the PIS and completing the consent page on Qualtrics participants will then be presented with the demographic, PHQ-9, GAD-7 and BSL-23 questionnaires which will be used to determine later allocation of their data to one of the three group. They will then be presented with the PERCI, FFMQ-15 and DERS.

Intervention type: OTHER
Intervention: Online self-report questionnaire completion
Description: After reading the PIS and completing the consent page on Qualtrics participants will then be presented with the demographic, PHQ-9, GAD-7 and BSL-23 questionnaires which will be used to determine later allocation of their data to one of the three group. They will then be presented with the PERCI, FFMQ-15 and DERS.
Study: NCT06192381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-Based Learning Module (WBL)
Description: To ensure a uniform starting point, the participants were recruited via faculty website and students' academic counseling services. At the baseline, after the initial assessment, the participants were randomized at a 1:1 allocation ratio into the following groups: 1) traditional health education group (control group) (n = 68) who received health education with traditional face-to-face method; 2) web-based health education group (intervention group) (n = 68) who received health education with Web-Based Learning Module (WBL).
Study: NCT04784429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kenevo or C-Leg 4
Description: Kenevo fitted to subjects walking slower than 0.8 m/s as measured by the 2-minute Walk Test. C-Leg 4 fitted to subjects walking faster than 0.8 m/s.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non microprocessor controlled knee (NMPK)
Description: NMPK consistent with current standards of care
Study: NCT06413901

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TIP
Description: TIP hypospadias repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TIP
Description: TIP hypospadias repair
Study: NCT05236439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interposition supraciliary implant
Description: Surgical placement of SV22 interposition supraciliary implant in the supraciliary space
Study: NCT05902832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EmotiPlay
Description: EmotiPlay is a computer-based intervention program, designed to enhance emotion recognition (ER) by addressing multiple modalities of emotional cues (facial expressions, tone of voice, body language),
Study: NCT04730570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Essential Coaching for Every Mother
Description: Essential Coaching for Every Mother consists of 53 standardized text messages that provide evidence-based information that women should be aware of related to caring for their newborn and maternal mental health. Messages are personalized with the name of the child. Messages sent from birth to six-weeks postpartum, with two messages sent per day in the first two weeks and a daily message for weeks 3-6. The following topics covered in Essential Coaching for Every Mother include anxiety, depression, maternal self-care, postnatal follow-up, breastfeeding or formula feeding, infant concerns, cord care, well-baby care, normal development, crying, and safe sleep. Women who receive the messages will be able to self-select breastfeeding or formula feeding messages.
Study: NCT05127122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles
Description: Injectable

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles
Description: Injectable
Study: NCT06560047

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Catheter ablation
Description: Catheter ablation with pulmonary vein isolation will be the study intervention. Patients randomized to the intervention arm will undergo catheter ablation within six weeks of randomization. In the waiting-time for ablation, patients will receive standard treatment for AF and HF, as per current guideline recommendations. Catheter ablation will be performed at one of six high-volume ablation centers in Denmark. Mode of catheter ablation will be at the discretion of the operator. Radiofrequency ablation, cryo-balloon ablation and pulsed-field ablation will be utilized. The treating physician should ensure successful pulmonary vein isolation after ablation with either post-procedural mapping or pacing, as per current standards. Only pulmonary vein isolation will be performed during the ablation procedure.
Study: NCT06388499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TECC (Telerehabilitation and Exercise for Chronic Conditions)
Description: Exercise: Synchronous group exercise sessions will be delivered weekly via videoconferencing by a physiotherapist. Recordings of exercise sessions will be made available. Participants will be advised to perform additional exercise sessions at their own convenience to supplement the synchronous exercise sessions and facilitate adherence to physical activity guidelines.~Education: A synchronous educational webinar will be delivered each week. These will be delivered by relevant healthcare professionals and explore various aspects of self-management of health and well-being. Recordings of the webinars will be made available to participants.~Social component: At the end of each weekly synchronous group exercise session, participants will have the opportunity to engage in a 10-15-minute synchronous online social interaction with other participants in their exercise group via videoconferencing.
Study: NCT05458648

Intervention type: PROCEDURE
Intervention: Cardiac Ablation for the treatment of persistent Atrial Fibrillation
Description: Patients participating in the study will undergo a cardiac ablation for the treatment of persistent atrial fibrillation.
Study: NCT06576271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4527363
Description: GSK4527363 will be administered to participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4527363
Description: GSK4527363 will be administered to participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4527363
Description: GSK4527363 will be administered to participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4527363
Description: GSK4527363 will be administered to participants.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching GSK4527363
Description: Placebo matching GSK4527363 will be administered to participants.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching GSK4527363
Description: Placebo matching GSK4527363 will be administered to participants.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching GSK4527363
Description: Placebo matching GSK4527363 will be administered to participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab will be administered to participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab will be administered to participants.
Study: NCT04727151

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAC01-HER2
Description: TAC01-HER2 and:~* fludarabine and cyclophosphamide, or~* clofarabine and cyclophosphamide, or~* bendamustine, or~* cyclophosphamide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAC01-HER2 plus pembrolizumab
Description: TAC01-HER2 plus pembrolizumab and:~* fludarabine and cyclophosphamide, or~* clofarabine and cyclophosphamide, or~* bendamustine, or~* cyclophosphamide
Study: NCT05550142

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose
Description: 50μg/dose
Study: NCT04779619

Intervention type: OTHER
Intervention: Online self-report questionnaire completion
Description: After reading the PIS and completing the consent page on Qualtrics participants will then be presented with the demographic, PHQ-9, GAD-7 and BSL-23 questionnaires which will be used to determine later allocation of their data to one of the three group. They will then be presented with the PERCI, FFMQ-15 and DERS.
Study: NCT05550142

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine High dose
Description: 100μg/dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline solution
Study: NCT05907824

Intervention type: OTHER
Intervention: Histopathological review, long-term prognosis and quality of life follow-up
Description: Histopathological review, long-term prognosis and quality of life follow-up

Intervention type: OTHER
Intervention: Histopathological review, long-term prognosis and quality of life follow-up
Description: Histopathological review, long-term prognosis and quality of life follow-up
Study: NCT05242328

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided erector spinae plane block
Description: Ultrasound-guided erector spinae plane block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical thoracoscopic intercostal nerve block
Description: surgical thoracoscopic intercostal nerve block
Study: NCT05675657

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Block
Description: The patients will receive general anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum Block Type III
Description: Patients will receive ultrasound-guided quadratus lumborum block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Patients will receive ultrasound-guided erector spinae plane block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.
Study: NCT06313580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogurt with added Spices
Description: Consumption of twice daily yogurt with added spices for four weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Yogurt without added Spices
Description: Consumption of twice daily yogurt without added spices for four weeks.
Study: NCT05977231

Intervention type: PROCEDURE
Intervention: BT
Description: A program of BT (including exercise and muscle training)

Intervention type: PROCEDURE
Intervention: bPFMT
Description: A bPFMT program at home

Intervention type: PROCEDURE
Intervention: iVES
Description: An iVES program at home

Intervention type: PROCEDURE
Intervention: BT + bPFMT
Description: Combination of BT and bPFMT

Intervention type: PROCEDURE
Intervention: BT + iVES
Description: Combination of BT and iVES

Intervention type: PROCEDURE
Intervention: bPFMT + iVES
Description: Combination of bPFMT and iVES
Study: NCT05264025

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexofenadine
Description: tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet
Study: NCT05877300

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cellspan™ Esophageal Implant-Adult (CEI)
Description: The CEI is a combination product consisting of an engineered synthetic scaffold (device constituent) seeded and cultured with the patient's adipose derived mesenchymal stromal cells (biologic constituent), intended to stimulate regeneration of a structurally intact, living biologic esophageal conduit, in patients requiring full circumferential esophageal reconstruction up to 6 cm segment in length.
Study: NCT05081453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pavlik harness
Description: The application of a pavlik harness will be carried out in the intervention group. It will follow a protocol similar to that of the treatment of hip dysplasia in terms of follow-up and safety
Study: NCT06289075

Intervention type: OTHER
Intervention: Intensive Care Unit (ICU) treatment
Description: ICU treatment
Study: NCT06190847

Intervention type: OTHER
Intervention: regular chemoradiotherapy
Description: regular chemoradiotherapy
Study: NCT06100133

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone ester
Description: Up to 100g ketone ester daily for 56 days
Study: NCT06273644

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrates
Description: Half of the patients will initially follow Diet Plan A with 60-65 E% carbohydrates for 4 weeks, followed by a 4-week washout period, and then Diet Plan B with 40-45 E% carbohydrates for 4 weeks. The other half will start with Diet Plan B for 4 weeks, followed by a 4-week washout period, and then Diet Plan A for 4 weeks . Diet Plans A and B contain recommended and adequate nutrients according to the Nordic Nutrition Recommendations 2023 (NNR2023) for maintaining a stable weight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrates
Description: Half of the patients will initially follow Diet Plan A with 60-65 E% carbohydrates for 4 weeks, followed by a 4-week washout period, and then Diet Plan B with 40-45 E% carbohydrates for 4 weeks. The other half will start with Diet Plan B for 4 weeks, followed by a 4-week washout period, and then Diet Plan A for 4 weeks . Diet Plans A and B contain recommended and adequate nutrients according to the Nordic Nutrition Recommendations 2023 (NNR2023) for maintaining a stable weight.
Study: NCT06270264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the Nociception level index monitoring
Description: Nociception level index (NOL) monitoring (Medasense) is a non- invasive device differentiated from its alternatives by the use of five parameters: heart rate, heart rate variability, skin conductance level, photo-plethysmography waveform amplitude, number of skin conductance fluctuations, and their time derivatives.
Study: NCT05342389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: a PD-1 antibody

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib Mesylate
Description: an oral tyrosine kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: an oral tyrosine kinase inhibitor
Study: NCT05648942

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Anemia testing
Description: Patients will undergo a point of care test to identify possible anemia
Study: NCT05312151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Open label